Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Sells $14,292.30 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,562 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $9.15, for a total transaction of $14,292.30. Following the completion of the transaction, the chief accounting officer now directly owns 28,189 shares of the company’s stock, valued at $257,929.35. This represents a 5.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vir Biotechnology Stock Performance

VIR opened at $9.65 on Monday. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The company has a market capitalization of $1.33 billion, a P/E ratio of -2.46 and a beta of 0.64. The stock has a fifty day moving average of $9.13 and a 200-day moving average of $8.46.

Wall Street Analysts Forecast Growth

VIR has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, January 31st. Leerink Partners raised their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Barclays reduced their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $34.83.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of VIR. The Manufacturers Life Insurance Company lifted its holdings in shares of Vir Biotechnology by 7.9% during the second quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock worth $436,000 after buying an additional 3,605 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Vir Biotechnology by 27.8% during the third quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company’s stock worth $430,000 after buying an additional 12,511 shares in the last quarter. nVerses Capital LLC acquired a new position in Vir Biotechnology in the third quarter valued at about $56,000. Blue Trust Inc. raised its stake in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Vir Biotechnology by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company’s stock valued at $197,000 after purchasing an additional 10,294 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).